Genomics Technologies and Diseases
Genetic modifiers in mice: the example of the fragile X mouse modelErrijgers V. · Kooy R.F.
Department of Medical Genetics, University of Antwerp, Antwerp (Belgium)
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Modifiers play an important role in most, if not all human diseases, and mouse models. For some disease models, such as the cystic fibrosis knockout mouse model, the effect of genetic factors other than the causative mutation has been well established and a modifier gene has been mapped. For other mouse models, including those of the fragile X syndrome, a common form of inherited mental retardation, controversies between test results obtained in different laboratories have been well recognized. Yet, the possibility that modifiers could at least explain part of the discrepancies is only scarcely mentioned. In this review we compare the test results obtained in different laboratories and provide evidence that modifiers may affect disease severity in the fragile X knockout mouse.
© 2004 S. Karger AG, Basel
- Bailey DB, Hatton DD, Tassone F, Skinner M, Taylor AK: Variability in FMRP and early development in males with fragile X syndrome. Am J Ment Retard 106:16–27 (2001).
- Bakker CE, Oostra BA: Understanding fragile X syndrome: insights from animal models. Cytogenet Genome Res 100:111–123 (2003).
- Bakker CE, Verheij C, Willemsen R, van der Helm R, Oerlemans F, Vermey M, Bygrave A, Hoogeveen AT, Oostra BA, Reyniers E, De Boulle K, D’Hooge R, Cras P, van Velzen D, Nagels G, Martin J-J, De Deyn PP, Darby JK, Willems PJ: Fmr1 knockout mice: a model to study fragile X mental retardation. Cell 78:23–33 (1994).
- Brown V, Jin P, Ceman S, Darnell J, O’Donnell WT, Tenenbaum SA, Jin X, Feng Y, Wilkinson KD, Keene JD, Darnell RB, Warren ST: Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 107:477–487 (2001).
- Buchner DA, Trudeau M, Meisler MH: SCNM1, a putative RNA splicing factor that modifies disease severity in mice. Science 301:967–969 (2003).
- Burgess DL, Kohrman DC, Galt J, Plummer NW, Jones JM, Spear B, Meisler MH: Mutation of a new sodium channel gene, Scn8a, in the mouse mutant “motor endplate disease”. Nat Genet 10:461–465 (1995).
- Ceman S, Brown V, Warren ST: Isolation of an FMRP-associated messenger ribonucleoprotein particle and identification of nucleolin and the fragile X-related proteins as components of the complex. Mol Cell Biol 19:7925–7932 (1999).
- Chen L, Toth M: Fragile X mice develop sensory hyperreactivity to auditory stimuli. Neuroscience 103:1043–1050 (2001).
- Crabbe JC, Wahlsten D, Dudek BC: Genetics of mouse behavior: interactions with laboratory environment. Science 284:1670–1672 (1999).
- D’Hooge R, De Deyn PP: Applications of the Morris water maze in the study of learning and memory. Brain Res Rev 36:60–90 (2001).
- D’Hooge R, Nagels G, Franck F, Bakker CE, Reyniers E, Storm K, Kooy RF, Oostra BA, Willems PJ, De Deyn PP: Mildly impaired water maze performance in male Fmr1 knockout mice. Neuroscience 76:367–376 (1997).
- Darvasi A: Experimental strategies for the genetic dissection of complex traits in animal models. Nat Genet 18:19–24 (1998).
- De Boulle K, Verkerk AJMH, Reyniers E, Vits L, Hendrickx J, van Roy B, van den Bos F, de Graaff E, Oostra BA, Willems PJ: A point mutation in the FMR1 gene associated with fragile X mental retardation. Nat Genet 3:31–35 (1993).
- de Vries BBA, Wiegers AM, Smits APT, Mohkamsing S, Duivenvoorden HJ, Fryns J-P, Curfs LMG, Halley DJJ, Oostra BA, van den Ouweland AMW, Niermijer MF: Mental status of females with an FMR1 gene full mutation. Am J Hum Genet 58:1025–1032 (1996).
- Dobkin C, Rabe A, Dumas R, El Idrissi A, Haubenstock H, Brown WT: Fmr1 knockout mouse has a distinctive strain-specific learning impairment. Neuroscience 100:423–429 (2000).
- Ivanco TL, Greenough WT: Altered mossy fiber distributions in adult Fmr1 (FVB) knockout mice. Hippocampus 12:47–54 (2002).
Jin P, Warren ST: New insights into fragile X syndrome: from molecules to neurobehaviors. Trends Biochem Sci 28:152–158 (2003).
- Koch M: The neurobiology of startle. Prog Neurobiol 59:107–128 (1999).
Kooy RF, Willemsen R, Oostra BA: Fragile X syndrome at the turn of the century. Mol Med Today 6:194–199 (2000).
- Kooy RF: Of mice and the fragile X syndrome. Trends Genet 19:148–154 (2003).
- Kooy RF, D’Hooge R, Reyniers E, Bakker CE, Nagels G, De Boulle K, Storm K, Clincke G, De Deyn PP, Oostra BA, Willems PJ: Transgenic mouse model for the fragile X syndrome. Am J Med Genet 64:241–245 (1996).
- Laggerbauer B, Ostareck D, Keidel EM, Ostareck-Lederer A, Fischer U: Evidence that fragile X mental retardation protein is a negative regulator of translation. Hum Mol Genet 10:329–338 (2001).
- Li Z, Zhang Y, Ku L, Wilkinson KD, Warren ST, Feng Y: The fragile X mental retardation protein inhibits translation via interacting with mRNA. Nucleic Acids Res 29:2276–2283 (2001).
- Mineur YS, Sluyter F, de Wit S, Oostra BA, Crusio WE: Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse. Hippocampus 12:39–46 (2002).
- Morris RGM, Garrud P, Rawlins JNP, O’Keefe J: Place navigation impaired in rats with hippocampal lesions. Nature 297:681–683 (1982).
- Nadeau JH: Modifier genes in mice and humans. Nat Rev Genet 2:165–174 (2001).
- Nadeau JH: Modifier genes and protective alleles in humans and mice. Curr Opin Genet Dev 13:290–295 (2003).
- Nielsen DM, Derber WJ, McClellan DA, Crnic LS: Alterations in the auditory startle response in Fmr1 targeted mutant mouse models of fragile X syndrome. Brain Res 927:8–17 (2002).
- Paradee W, Melikian HE, Rasmussen DE, Kenneson A, Conn PJ, Warren ST: Fragile X mouse: strain effects of knockout phenotype and evidence suggesting deficient amygdala function. Neuroscience 94:185–192 (1999).
- Peier AM, McIlwain KL, Kenneson A, Warren ST, Paylor R, Nelson DL: (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum Mol Genet 9:1145–1159 (2000).
- Rozmahel R, Wilschanski M, Matin A, Plyte S, Oliver M, Auerbach W, Moore A, Forstner J, Durie P, Nadeau J, Bear C, Tsui L-C: Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nat Genet 12:280–287 (1996).
- Schaeffer C, Bardoni B, Mandel JL, Ehresmann B, Ehresmann C, Moine H: The fragile X mental retardation protein binds specifically to its mRNA via a purine quartet motif. EMBO J 20:4803–4813 (2001).
- Schwegler H, Crusio WE: Correlations between radial-maze learning and structural variations of septum and hippocampus in rodents. Behav Brain Res 67:29–41 (1995).
- Talbot CJ, Nicod A, Cherny SS, Fulker DW, Collins AC, Flint J: High-resolution mapping of quantitative trait loci in outbred mice. Nat Genet 21:305–308 (1999).
- Van Dam D, D’Hooge R, Hauben U, Reyniers E, Gantois I, Bakker CE, Oostra BA, Kooy RF, De Deyn PP: Spatial learning, contextual fear conditioning and conditioned emotional response in Fmr1 knockout mice. Behav Brain Res 117:127–136 (2000).
- Verkerk AJMH, Pieretti M, Sutcliffe JS, Fu Y-H, Kuhl DPA, Pizzuti A, Reiner O, Richards S, Victoria MF, Zhang F, Eussen BE, van Ommen G-JB, Blonden LAJ, Riggins GJ, Chastain JL, Kunst CB, Galjaard H, Caskey CT, Nelson DL, Oostra BA, Warren ST: Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65:905–914 (1991).
- Wade CM, Kulbokas III EJ, Kirby AW, Zody MC, Mullikin JC, Lander ES, Lindblad-Toh K, Daly MJ: The mosaic structure of variation in the laboratory mouse genome. Nature 420:574–578 (2002).
- Zielenski J, Corey M, Rozmahel R, Markiewicz D, Aznarez I, Casals T, Larriba S, Mercier B, Cutting GR, Krebsova A, Macek Jr M, Langfelder-Schwind E, Marshall BC, DeCelie-Germana J, Claustres M, Palacio A, Bal J, Nowakowska A, Ferec C, Estivill X, Durie P, Tsui L-C: Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13. Nat Genet 22:128–129 (1999).
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.